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Abstract  
We have used brain tissue from clinically well-documented and neuropathologically confirmed cases of sporadic 
Parkinson's disease to establish the transcriptomic expression profile of the medial and lateral substantia nigra. In 
addition, the superior frontal cortex was analyzed in a subset of the same cases. DNA oligonucleotide 
microarrays were employed, which provide whole human genome coverage. A total of 570 genes were found to 
be differentially regulated at a high level of significance. A large number of differentially regulated expressed 
sequence tags were also identified. Levels of mRNA sequences encoded by genes of key interest were validated 
by means of quantitative realtime polymerase chain reaction (PCR). Comparing three different normalization 
procedures, results based on the recently published GeneChip Robust Multi Array algorithm were found to be 
the most accurate predictor of realtime PCR results. Several new candidate genes which map to PARK loci are 
reported. In addition, the DNAJ family of chaperones is discussed in the context of Parkinson's disease 
pathogenesis. 




Parkinson's disease [PD; Online Mendelian Inheritance in Man (OMIM) 168600] is the second most common 
neurodegenerative disorder after Alzheimer's disease. Due to demographic ageing [World Health Organization 
(WHO) Health Report 1998], the incidence of this devastating neurological disorder is expected to increase 
severalfold over the next decades. A number of mutations have been described which cause rare familial forms 
of the disease [1-10], but the vast majority (>85%) of all PD cases are considered sporadic. In the latter 
"idiopathic" form of PD both genetic and environmental factors are expected to contribute to disease 
development in keeping with the concept of PD being a complex genetic disorder. Current thinking about the 
pathogenesis of PD is increasingly focused on disease-causing pathways, some of which have been identified in 
connection with the rare familial forms of PD. These include the ubiquitin-proteasome system, the mitochondrial 
respiratory chain and, notably, the alpha-synuclein pathway and its associated genes. We are establishing a 
comprehensive molecular pathological database of sporadic PD to provide a basis for studies into these and other 
functionally related "PD pathways". 
We have studied a clinically well-documented and neuropathologically confirmed cohort of idiopathic PD cases. 
All cases showed alpha-synuclein immunopathology. Two cases showed additional Alzheimer's disease 
pathology (an expected frequency), one developed dementia, allowing a diagnosis of Parkinson's disease with 
dementia (PDD) and one could be classified as dementia with Lewy bodies (DLB) based on clinical course and 
alpha-synuclein pathology. 
The international neuropathological consensus definition of sporadic PD includes an assessment of alpha-
synuclein status of the whole brain (http://www.ICDNS.org). However, the human substantia nigra (SN) still 
represents a key anatomical region of interest in PD because this is the brain area which exhibits extensive and 
most consistent tissue damage in the disease. Here, characteristic degeneration of dopaminergic nerve cells is 
easy to recognise. In addition, remaining nerve cells typically show Lewy bodies. Once more than half of the 
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existing nerve cell population has died, parkinsonism manifests itself clinically. It is well known that the lateral 
SN shows the most pronounced degeneration [11 ]. 
We have determined the whole genome expression profile (complete transcriptome) of the adult SN in 15 PD 
brain donors, in seven controls (brain donors without neurological disease) and in one disease-specific control (a 
neuropathologically confirmed case of multiple sclerosis) with histologically intact nigra. In addition, we have 
compared the expression profile of the lateral and medial SN to the frontal cerebral cortex in a subset of the same 
cases. 
Materials and methods 
Case material 
The human brain tissue for this study was obtained from the UK Parkinson's Disease Society Tissue Bank at 
Imperial College London and from the Laboratory of Neuropathology of the University of Liège. In addition, 
one disease-specific control was obtained from the UK Multiple Sclerosis Society Tissue Bank at Imperial 
College London. The basic clinical and neuropathological characteristics of the cases used in the study are 
shown in Table 1. A detailed description of the clinical and histological findings in each case will be provided 
elsewhere (Moran et al., in preparation). In total, 47 individual tissue samples were analyzed, i.e. 15 samples of 
medial parkinsonian SN, nine samples of lateral parkinsonian SN, eight medial nigra control samples and seven 
lateral nigra control samples. Lateral and medial nigra samples were from the same cases. In addition, the frontal 
cerebral cortex was analyzed in five of the PD cases and in three of the controls. 
 
RNA extraction 
Total RNA was extracted from freshly dissected brain tissue, snap-frozen and kept at -70°C until further use. For 
nucleic acid extraction, the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) was used according to the 
manufacturer's protocols (http://www.qiagen.com). Tissue samples were mechanically disrupted using a rotary 
homogenizer, lysed in buffer containing guanidine isothiocyanate (GITC) and then further homogenized 
(shredder tubes, Qiagen). The resulting homogenate was passed through the RNeasy mini column containing the 
RNeasy silica gel membrane that selectively binds RNA. Total RNA was resuspended in RNAse-free water 
(http://www.eppendorf.com). RNA yields were determined using a spectrophotometer (GeneQuantPro), and the 
quality was assessed using agarose gel electrophoresis. RNA samples were stored at -80°C. 
Preparation of target cRNA for microarrays 
Target cRNA for microarray analysis was prepared following the manufacturer's protocol 
(http://www.affymetrix.com) and, essentially, as described previously [12]. In brief, total RNA was used for 
cDNA synthesis employing the Super-Script double-stranded cDNA synthesis kit (Superscript Choice System, 
Life Technologies, Gaithersburg, MD) with the T7-(dT)24 primer. In vitro transcription was performed using the 
Enzo-IVT kit (Enzo BioArray High Yield RNA Transcript Labelling Kit, Enzo Diagnostics, Farmingdale, New 
York, USA). The resulting biotin-labelled cRNA was purified employing the RNeasy Mini Kit and then 
fragmented in buffer (40 mM Tris-acetate pH 8.1, 100 mM KOAc, and 30 mM MgOAc) at 95°C for 35 min. A 
quality check using Affymetrix Test3 arrays was carried out, and the fragmented biotinylated cRNA was then 
hybridized to Affymetrix Human Genome U133A and U133B gene chips (Affymetrix, Santa Clara, CA, USA). 
This array set contained 44,760 unique human probe sets representing more than 39,000 transcripts and 
approximately 6,000 expressed sequence tags (ESTs). The arrays were labelled with streptavidin-phycoerythrin 
and then washed before scanning in a Gene Array scanner (Affymetrix). 
Microarray data analysis 
Analysis output (CHP) files were generated using Affymetrix Microarray Suite 5.0 software (MAS5.0). The 94 
microarrays employed in this study were scaled to the same target intensity. CHP and cell intensity (CEL) files 
of the microarrays were read using ArrayAssist software (versions 3.0 and 3.2, respectively; Stratagene 
Interaction Explorer; http://www.stratagene.com). Aggregate intensity values were derived applying the 
GeneChip Robust Multi Array (GC-RMA) algorithm [13] and the Probe Logarithmic Intensity Error (PLIER; 
http://www.affymetrix.com), respectively. Transcripts were defined as statistically significant (two-class 
unpaired significance analysis with unequal variance) when they met the criteria of (a) p<0.001 and (b) an 
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absolute difference in expression of 1.0 log unit (log with base 2) (Fig. 1a). For comparative purposes, 
significance analysis was carried out with or without error stabilization (variance inflation which increases 
precision of the analysis for very low expression values) and p value correction for multiple testing [Bonferroni 
or Benjamini-Hochberg false-discovery rate (FDR)], respectively, p values corrected according to the Benjamini-
Hochberg method are given in the following text (no error stabilization/variance inflation) except where 
explicitly indicated. 
Table   1   Clinical   and   neuropathological characteristics of cases 








Tissue pHa Postmortem 
delay (h) 
HU_133 A 
and B array 
SN medial 
HU_133 A 
and B array 
SN lateral 
Parkinson's disease        
1 F 87 12 975 6.7 - Yesb Yes 
2 M 83 9 1,182 6.5 - Yes Yes 
3c M 68 3 1,422 6.6 15.0 Yesb Yes 
4 M 78 10 1,560 6.5 21.7 Yes Yes 
5 F 86 15 1,299 6.4 5.5 Yes Yes 
6 F 81 14 1,330 6.4 17.5 Yes Yes 
7 F 85 18 1,286 6.2 13.5 Yes Yes 
8 M 75 34 1,351 6.1 1.3 Yes ND 
9 M 76 27 1,282 6.0 17.0 Yes ND 
10 F 76 10 1,144 6.2 13.5 Yes Yes 
11 M 82 18 1,251 6.2 13.5 Yes Yes 
12 M 76 7 1,313 6.3 15.0 Yesb ND 
13 M 89 3 1,400 6.0 16.0 Yes ND 
14c F 84 11 1,089 6.1 15 Yesb ND 
15 M 76 10 1,291 6.7 9.7 Yesb ND 
Mean±SD  80±5.7 13.4±8.3 1,278±142 6.3±0.23 13.4±5.2 - - 
Range  (68-89) (3-34) (975-1,560) (6.0-6.7) (1.3-21.7) - - 
Ratio M to F 9:6 - - - - - - - 
Controls         
16 M 76 NA 1,456 6.8 - Yes Yes 
17 M 77 NA l,484d 6.7 4 Yesb Yes 
18 M 81 NA 1,410 6.8 30 Yesb ND 
19 M 71 NA 1,430 6.3 4 Yes Yes 
20 F 77 NA 1,052 6.0 9 Yes Yes 
21e F 80 NA 1,029 6.0 13.0 Yes Yes 
22 M 46 NA 1,160 6.6 NA Yes Yes 
23 M 57 NA 1,458 6.0 5.0 Yesb Yes 
Mean±SD  70.6±12.5 NA 1,309±194 6.4±0.37 10.8±10.0   
Range  (46-81) NA (1,029-1,484) (6.0-6.8) (4-30)   
Ratio M to F 6:2 - - - - - - - 
F Female, M male, NA not applicable, ND not determined, - information not available  
aBoth tissue pH and pH of cerebrospinal fluid (CSF) were determined  
bCerebral cortex was analyzed incases 1, 3, 12, 14, 15, 17, 18 and 23  
cNeuropathological changes consistent with Alzheimer's disease  
dFixed brain weight  
eDisease control case 
 
Real-time PCR assay 
DNase-treated RNA was reverse-transcribed with random decamers using a RetroScript kit (Ambion; 
http://www. ambion.com) following the manufacturer's protocol and then stored at -20°C. Two internal controls 
were selected based on their consistent expression in normal human brain tissue [14] and as also confirmed in 
our set of cases: beclin 1 [coiled-coil, myosin-like BCL2-interacting protein (BECN1)] and glutaminyl-tRNA 
synthetase (QARS). Primers for the above control sequences and alpha-synuclein (SNCA), orphan nuclear 
receptor (NR4A2 or Nurr1), mitochondrial complex I subunit (NDUFA9) and ubiquitin carboxyl-terminal 
esterase L1 (UCHL1) were designed using MacVector 7.0 software (Accelrys, Cambridge, UK) and synthesised 
by Sigma Genosys, Haverhill, UK (http://www.sigma-genosys. com). Primer sequences are shown in Table 2. 
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Where possible, primers were designed to span intron sequences to detect any genomic contamination. 
Real-time PCR was performed using Sybr Green I Mastermix (Applied Biosystems, Foster City, CA, USA; 
http://appliedbiosystems.com) using an ABI PRISM 7700 Sequence Detection System. Each reaction was run in 
triplicate and contained 1 µl of cDNA template along with 300 nM primer in a final reaction volume of 25 µl. 
Cycling parameters were 95°C for 10 min, 40 cycles at 95°C for 15 s, 60°C (annealing and extension) for 1 min, 
with a final extension step at 78-84°C for 20 s. Melting curves were determined using Dissociation Curves 1.0 
software (Applied Biosystems). In addition, samples were run on a 3% agarose gel to control for amplification 
product specificity. 
Real-time PCR data were processed using SDS 1.7 software (Applied Biosystems). Data were exported from 
SDS 1.7, and a normalization factor was calculated, derived from the geometric mean of the internal control 
genes [15]. Fold differences (relative expression) in PD samples compared to controls were determined using 
Data Analysis software for Real-Time PCR (DART-PCR Version 1.0) [16]. 
Table 2  Primer sequences used for quantitative real-time PCR 
Gene 
symbol 






Control genes     
BECN1 TTCACTCTGATTGGGGAGGCATC 23 336 80 
 
Beclin 1 (coiled-coil, 
myosin-like BCL2-
interacting protein) 
CACTATCTTGCGGTTCTTTTCCACG 25   
QARS CCATAATACTCTGCCTTCACCCTG 24 559 80 
 
Glutaminyl-tRNA 
synthetase AAGATGTGGCTCCATTGTGGTTTG 24   
Genes assayed     
NURR1 GGCTATGGTCACAGAGAGACACGG 24 306 80 
 
Orphan nuclear 
receptor CATTCCAGTTCCTTTGAAGTGCTTG 25   
SNCA TCAAAAAGGACCAGTTGGGCAAG 23 315 80 
 
Alpha-synuclein 
ACCGAAATGCTGAGTGGGGG 20   
UCHL1 TGGACGAATGCCTTTTCCG 19 372 82 
 
Ubiquitin carboxyl-
terminal esterase L1 GGGGAGAATGCTTCACCATCTG 22   
NDUFA9 TCCTGATGCCAATGGGAAATCC 22 274 78 
 
Mitochondrial complex 
I subunit TTCCAGTGGTGTTGCCTGAATACC 24   
Tm Melting temperature 
 
Results 
We have found that on average, 15,600 (35%) of all genes in the SN received present calls. The difference 
between PD nigra and control appeared to be predominantly quantitative rather than qualitative, with more than 
85% of all genes being shared. A direct comparison of the different normalization procedures (Fig. 1b) revealed 
very significant differences in the number of identified differentially regulated genes at low significance levels. 
Results obtained with the three different algorithms were more comparable at p<0.001, although not all priority 
genes detected using the different algorithms were identical. This demonstrates the need to assess the quality of 
microarray algorithms through external validation (Fig. 1c). 
Validation of microarray-based results was achieved using quantitative real-time polymerase chain reaction 
(qRT-PCR) analysis. Samples from the original RNA extraction used for running the gene chips and additional 
RNA from independant extractions of the same brain tissue blocks were used, and a close match was observed, 
with excellent preservation of the original trend (Fig. 1c). The overall best match was observed for the GC-RMA 
algorithm. This was in keeping with recently published studies [13]. We therefore decided to use the GC-RMA 
algorithm as the "gold standard" for our analysis. Further validation of the results obtained in this study came 
from another microarray project [17]. We compared a list of genes (Table 3) for consistency of expression, up- 
or down-regulation of the genes under study and preservation of expression trends within each group and found a 
perfect match of trend for every single probe checked (r= 0.864, Spearman). Accordingly, the list of genes 
shown in Table 3 can be considered as confirmed PD-associated sequences or a first PD expression signature. 
Supplemental Figure 1 shows the pathway relationships of these genes (PathwayAssist programme). 
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Fig. 1 a Volcano plot of differentially expressed genes in substantia nigra. The x axis shows differential expression (DE; 
logarithmic scale), the y axis indicates the respective p value of each sequence. The sequences coloured in red show a differential expression 
greater or smaller than one (logarithm with base 2, i.e. one log unit representing a 100% difference) and p values smaller than 0.001. There 
are 570 probe sets fulfilling these criteria. b Comparison of the number of "significant genes" as detected by GC-RMA-, PLIER- and 
MAS5.0-based analysis procedures. At p<0.05 (no variance inflation, no Bonferroni or Benjamini-Hochberg FDR correction) the PLIER 
algorithm which takes into account Affymetrix proprietary information on probe behaviour stands out by producing a very large number of 
significantly regulated genes. The number of significantly regulated genes as detected by the different algorithms compares rather well at 
p<0.001. This very stringent threshold leaves 570 significantly regulated genes according to the GC-RMA procedure (Fig. 2). For p values 
<0.05 and <0.01, a DE of 1 was also chosen. c Validation of microarray results. Predictions made on the basis of microarray results obtained 
following different normalization procedures were validated using qRT-PCR analysis. Values expected from GC-RMA-based analysis match 
qRT-PCR results most closely. Genes selected were chosen on the basis of their relevance for Parkinson's disease. GC-RMA-, PLIER- and 
MAS5.0-based algorithms are compared 
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Fig. 1 (continued) 
 
 
Fig. 2 Comparison of the number of significant genes in the medial and lateral substantia nigra. For the two analysis 
results on the left (medial and lateral nigra, respectively) only medial and lateral samples (PD vs control) were compared (two-class unpaired 
t test, unequal variance, variance inflation, Bonferroni p value correction). It is interesting to note that the observation that some highly 
significant genes appear to be "specific" to the lateral and medial nigra, respectively (235 and 86, respectively), is paralleled by the fact that 
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Probe set name GenBank 
number 
Description Our data 
(fold 
change) 
Zhang et al. 
2005a [17] 
(fold change) 
NFASC 214799_at AI821777 Brain expressed, X-linked 1 1.236 2.15 
PTDSR 212723_at AK021780 Phosphatidylserine receptor 1.179 2.41 
HSPB1 201841_s_at NM_001540 Heat-shock 27 kDa protein 1 1.502 1.69 
MKNK2 218205_s_at NM_017572 MAP kinase interacting serine/threonine 
kinase 2 
1.239 1.75 
TF 214064_at AI073407 Transferrin 1.053 1.90 
AMPH 205257_s_at NM_001635 Amphiphysin (Stiff-Man syndrome with 
breast cancer 128 kDa auto-antigen) 
-2.189 -3.20 
BEX1 218332_at NM_018476 Brain expressed, X-linked 1 -1.023 -1.96 
CDC42 214230_at R37664 Cell division cycle 42 (GTP binding 
protein, 25 kDa) 
-1.796 -3.20 
CHGB 204260_at NM_001819.1 Chromogranin B (secretogranin 1) -2.167 -2.60 
FGF13 205110_s_at NM_004114 Fibroblast growth factor 13 -2.708 -3.90 
MDH1 200978_at NM_005917 Malate dehydrogenase 1, NAD (soluble) -1.000 -2.37 
NEFL 221805_at AL537457 Neurofilament, light polypeptide 68 kDa -1.920 -2.78 
NSF 202395_at NM_006178 N-ethylmaleimide-sensitive factor -1.389 -2.62 
PC4 221727_at AA456973 Activated RNA polymerase II transcription 
cofactor 4 
-1.381 -2.06 
PRKAR2B 203680_at NM_002736 Protein kinase, cAMP-dependant, 
regulatory, type II, beta 
-1.777 -2.07 
SV2B 20555l_at NM_014848 Synaptic vesicle glycoprotein 2B -2.030 -2.29 
SYT1 203999_at AV731490 Synaptotagmin I -2.296 -3.01 
SNAP25 202508_s_at NM_003081 Synaptosomal-associated protein, 25 kDa -1.339 -1.98 
STMN2 203000_at BF967657 Stathmin-like 2 -1.761 -2.60 
SNX10 218404_at NM_013322 Sorting nexin 10 -1.171 -2.28 
RGS4 204337_at AL514445 Regulator of G-protein signalling 4 -2.120 -4.16 
NAD Nicotinamide adenine dinucleotide, cAMP cyclic adenosine monophosphate 
aThe paper by Zhang et al. (2005) [17] lists alternative probe set names for NEFL (221916_at) and SNAP25 (202507_s_at). Unlike the 
present study, the manuscript by Zhang et al. only reports results obtained using the Affymetrix HG_133A chip 
 
We identified 570 sequences ("priority genes") which passed the FDR correction and which were up- or down-
regulated at least twofold in the parkinsonian nigra (Fig. 1a). The ratio between up- and down-regulated 
messages was 1:6. The gene exhibiting the strongest loss of activity was tyrosine hydroxylase (probe 208291 s 
at, p = 5.29384e-06, DE = -3.88). The highest up-regulation observed was at three log units (800%) with p = 
7.14996e-05. The highest significance for differential regulation was obtained at p = 4.151 48e-08 for one EST 
at DE = -1.7. Using p<0.001 as the significance threshold and 0.1 log units (approximately 7% difference in 
expression) as the cut-off for differentially expressed mRNA sequences, 3,224 differentially regulated messages 
were identified. 
The Venn diagram in Fig. 2 shows the intersection of highly significant genes detected in the lateral and medial 
nigra compared with the total number of nigra genes. The medial and lateral nigra showed significant differences 
in expression for some genes (86 and 235, respectively). The 466 genes at the intersection of all three groups 
form the focus of our current analysis. Contained within this group of significant genes are a larger number of 
ESTs, suggesting that new pathways exist that have so far not been studied in relation to PD pathogenesis. 
However, it is clear that our list of 570 priority genes is a "working" list and will have to be constantly checked 
and amended if justified. 
Regarding differential regulation of PD-associated genes in the cerebral cortex, we found that some were co-
regulated with genes that were differentially expressed in the SN, but we also observed a number of apparently 
unique transcriptomic profiles which will need to be confirmed. Importantly, it appears that the number of genes 
showing co-regulation was too high (several observations made, work in progress) to be explained by chance 
alone, suggesting that at least at the level of the brain, PD may be considered a "systemic" disease. This would 
be in keeping with the widespread pathology revealed by alpha-synuclein immunocytochemistry. 
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'Gene ontology' (GO) [18] represents a controlled vocabulary to describe gene and gene product attributes in an 
organism (http://www.geneontology.org). The three organizing principles of GO are molecular function, 
biological process and cellular component. The 570 regulated sequences were grouped according to their 
corresponding annotations (Fig. 3). It is interesting that for each of the above GO categories, approximately half 
of the priority sequences could not be assigned to known GO categories (48.2, 54.8 and 50.8%, respectively). Of 
the priority sequences concerned, 51.8% possess known molecular functions (Fig. 3 a). The most highly 
represented transcripts in this group are involved in metal ion binding or act as receptors and enzymes. It is 
notable that a large number of sequences also play a role in DNA and nucleic acid binding. This is of special 
interest considering that fragmentation of nuclear DNA is an established finding in parkinsonian nigra [19, 20]. 
Transcripts representative of established cellular components (Fig. 3b) and known biological processes (Fig. 3c) 
accounted for slightly less than half (45.2 and 49.2%, respectively) of all regulated transcripts. In the cellular 
component group, genes and functions related to the nucleus, plasma membrane and the membrane fraction 
represent more than half of all priority transcripts. For the known biological processes, the highest percentage of 
transcripts were protein synthesis and breakdown (7.4%), signalling (7.9%), cell cycle, growth and development 
(9.5%) and transport (10.7%). Examining the distribution of highly regulated messages across pathways, only a 
small minority (11%) could be assigned to established metabolic cascades (GenMAPP/KEGG). The most highly 
represented include amino acid metabolism, translation factors, cellular signalling and cell adhesion (Fig. 3d). 
Interestingly, a number of our priority messages map to PARK loci, which are likely to harbour as yet 
unidentified PD-causing genes (Table 4). In addition to the gene mapping most closely to the Park10 locus [21], 
our full list includes all transcripts (priority genes only) derived from chromosome 1p, in view of a recent 
publication linking this region to risk and age-of-onset in PD [22]. However, overall and based on GO, only 
approximately 50% of these transcripts located on 1p have known molecular functions or form part of 
established biological processes or cellular components (data not shown). Three of the probes mapping to the lp 
region, which identify two proteins, i.e. cell division cycle 42 (CDC42) and vav 3 oncogene (VAV3), are 
involved in the integrin-mediated cell adhesion pathway (GenMAPP). Furthermore, looking at the list of priority 
genes in greater detail, several up-regulated transcripts were found to be members of the DNAJ family of heat-
shock proteins. These include DnaJ  (Hsp40) homologue subfamily B, member 1 (DNAJB1) and DnaJ (Hsp40) 
homologue, subfamily B, member 6 (DNAJB6). The DNAJ family provides important molecular chaperones 
which have been implicated in the assembly and disassembly of protein complexes, pro-tein folding, renaturation 
of denatured proteins, prevention of protein aggregation and protein export (http://www.ncbi.nlm.nih.gov/ 
entrez/query.fcgi?b=OMIM). Observed values for those genes were p = 0.000212164 and DE=1.4 for DNAJB6 
(209015_s_at), p = 0.007720513 and DE = 1.1 for DNAJB1 (200666_s_at) and p = 8.08917e-05 and DE=0.9 for 
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Fig. 3 Percentage of established genes (non-EST transcripts) serving a known molecular function, representing 
an established cellular component, participating in known biological processes and forming pathways. Genes are 
grouped according to their annotations as defined by Gene Ontology (GO; [18]). In the case of very small group sizes, summary headings 
were created for functionally related groups. Keys for resolving each summary group are given in Supplementary Table 1. a Per cent of non-
EST transcripts (51.8% of 570) serving a known molecular function. The insert (pie chart) shows that almost half (48.2%) of the "prioritised 
genes" do not have a known molecular function. b Per cent of differentially expressed non-EST transcripts (45.2% of 570) categorized 
according to the cellular component to which they belong. The insert (pie chart) shows that the majority of the "prioritised genes" do not 
have a known cellular function. c Per cent of non-EST transcripts (49.2% of 570) serving a known biological process. Genes were grouped 
according to the known biological process in which they are involved; the majority of transcripts (50.8%) cannot be assigned to Gene 
Ontology categories. d Per cent of highly significant non-EST sequences that are members of established pathways. The pie chart shows that 
only 11% (63/570) of the regulated transcripts can be assigned to known pathways (GenMAPP/ KEGG). Therefore, the vast majority (89%) 
of the "prioritised genes" are not part of a known gene regulatory network 
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Table 4  Gene sequences (priority genes only) that map to regions of established PD linkage 
PARK Chromosomal 
location 











chr2p13.3 MDH1 200978_at NM_005917 Malate dehydrogenase 1, NAD 
(soluble) 
-1.000 
PARK5b chr4p14 HIP2 225179_at AA161140 Huntington interacting protein 2 -1.254 
PARK10 
regionc 




chr1p13.3 VAV3 218807_at NM_006113 Vav 3 oncogene -1.383 
 
chr1p13.3 FLJ30525 225841_at BE502436 Hypothetical protein FLJ30525 -1.093 
 
chr1p13.3 LOC284611 226568_at AI478747 Hypothetical protein LOC284611 -1.602 
 








chr1p31.3 LOC163782 229125_at AA456955 Hypothetical protein LOC163782 -1.615 
 




chr1p34.2 HPCAL4 219671_at AL136591 Hippocalcin-like 4 -1.052 
 
chr1p34.3 NCDN 209556_at AB011179 Neurochondrin -1.018 
 








chr1p36 HSA9947 218608_at NM_022089 Putative ATPase -1.085 
 
chr1p36.1 CDC42 210232_at M35543 Cell division cycle 42 (GTP binding 
protein, 25 kDa) 
-1.946 
 
chr1p36.1 CDC42 214230_at R37664 Cell division cycle 42 (GTP binding 
protein, 25 kDa) 
-1.796 
 
chr1p36.1-p35 RAP1GA1 203911_at NM_002885 RAP1, GTPase activating protein 1 -1.020 
 
chr1p36.31- p36.11 BACH 208002_s_at NM_007274 Brain acyl-CoA hydrolase -1.696 
 
chr1pter-p22.2 RIMS3 204730_at NM_014747 Regulating synaptic membrane 
exocytosis 3 
-1.417 
PARK11 chr2q36.3 FLJ20701 219093_at NM_017933 Hypothetical protein FLJ20701 -1.002 
 
chr2q36.3 SLC16A14 238029_s_at R15072 Solute carrier family 16 




chr2q37.3 BOK 223349_s_at BE614255 BCL2-related ovarian killer 1.202 
 
chr2q37.3 LRRFIP1 223492_s_at BC004958 Leucine-rich repeat (in FLII) 
interacting protein 1 
-1.155 
ATPase Adenosinetriphosphatase 
aAll probes listed were tested using the Benjamini and Hochberg FDR model 
bUCHL1 is also a member of the list of priority genes  
cSome genes associated with risk and age-of-onset in PD are localised to chromosome 1p [22] 
dLocated within the linkage interval encompassing PARK10 [21] 
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Fig. 4 Identification of novel PD-associated genes belonging to the DnaJ family of heat-shock proteins which 
have been implicated in protein folding and protein complex dissociation (OMIM). The pathway schematic illustrates 
that binding of HERPUD1 (homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1) with the 
proteasome [28, 29] has a negative effect on the regulation and expression of DnaJ (Hsp40) homolog, subfamily B, member 1 (DNAJB1) 




The goal of this research programme is to answer the question of which differences in gene expression are 
responsible for the preferential susceptibility of dopaminergic nerve cells of the SN to dysfunction and eventual 
cell death. We present for the first time a whole genome expression analysis of the SN of 15 cases of 
neuropathologically confirmed PD and 8 controls. We have observed a number of highly significant expression 
differences in this study, and it is important to bear in mind that we have analyzed RNA extracted from whole-
tissue rather than individual cell types, and that expression differences are likely to be a reflection of disease 
affecting nerve cells as well as glia. We have found that less than 50% of the sequences interrogated by the gene 
chips were detectable in the SN. Therefore, approximately half of all human genes may be excluded from the 
search for genes that are of relevance in Parkinson's disease. At the same time we find that the difference 
between the parkinsonian nigra and control tissue is remarkably quantitative rather than predominantly 
qualitative. 
Only a few publications have so far detailed transcriptomic information on the parkinsonian nigra, and in those 
studies, genome coverage was restricted to either small Affymetrix HG Focus arrays [23] or the HG 133A array 
only [17, 24]. We compared the published gene lists of all three studies and checked for overlap (consistency), 
examining in detail all genes that are shared between at least two of the data sets. While the study by Hauser et 
al. 2005 [24] provides limited published information, and none of the top candidates of Grunblatt et al. 2004 [23] 
could be confirmed in our data set (matching results with seven down-regulated transcripts only, i.e. GBE1, 
ALDH 1A1, TRIM36, SLC18A2P, TMEM4, HIP2, and NR4A2), we observed excellent agreement between the 
A chip gene list published by Zhang et al. 2005 [17] and our own data (their study only used the HG_133A 
chip). 
A potentially very important finding of this study concerns a series of 25 sequences which are highly 
differentially regulated in PD and which map to known PARK loci. Accordingly, these sequences may play a 
role in sporadic PD and represent candidates for as yet unidentified disease-causing genes. Details of these 
candidate genes are given in Table 4. 
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We and others believe that dysfunction in the ubiquitin-proteasome system and cellular stress represent 
mechanisms behind the irreversible loss of dopaminergic neurones in PD (Duke et al., submitted). Dysfunction 
of the endoplasmic reticulum (ER) has also been proposed. In this study, we report increased levels of 
HERPUD1 mRNA in parkinsonian SN, which is the product of a gene that encodes an ER resident protein which 
is up-regulated in response to ER stress. It is well known that the accumulation of misfolded proteins in ER 
triggers an "unfolded protein response" (UPR), which increases transcription of genes encoding for ER 
chaperones and enzymes associated with ER protein degradation [25]. In the normal brain HERPUD1 has been 
localised to neurones, and it is found in activated microglia in senile plaques in the brains of Alzheimer's disease 
patients [26]. A microarray study of a 6-hydroxydopamine (6-OHDA)-treated dopaminergic cell line also shows 
that the neurotoxin stimulates pathways associated with cellular stress and the UPR accompanied by the 
expression of HERPUD1 [27]. The schematic pathway shown in Fig. 4 illustrates the interaction between 
homocys teine-inducible, ER stress-inducible, ubiquitin-like domain member 1 (HERPUD1; 217168_s_at, p = 
0.00 2316407, DE= 0.53) and the proteasome [28, 29], which is known to negatively influence expression of 
DNAJB1 [30] and downstream DNAJB6 [31]. DNAJB1 is involved in biological processes (GO) associated with 
chaperone-cofactor-dependant protein folding (i.e. assisting in the covalent and non-covalent assembly of post-
translational proteins and single-chain polypeptides or multi-subunit complexes into the correct tertiary 
structure) and has a known molecular function interacting selectively with unfolded protein. 
Future work will focus on the detailed and individualised expression profile of the priority sequences described 
here as well as additional members of this data set across various PD brain regions, their cellular localisation in 
different cell types and a study of their biological function in pathways in vitro and in vivo. Furthermore, a 
detailed analysis of individual genome usage by each PD case in relation to neuropathological and clinical 
features will be performed. Finally, we are planning to link our transcriptomic data to additional data layers 
(proteomics, metabonomics and morphonomics) to obtain a more holistic and refined picture of PD in the 
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